Interim Report January-September 2023
Nanoform published its Q3 2023 interim report on November 22, 2023, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.
Nanoform at CPHI Barcelona 2023 – Chemicals Knowledge Hub Interview
In this interview filmed at CPHI Barcelona, Nanoform CCO Christian…
Future-proofing drug development with nanoparticle engineering
Nanoparticle formulations are a key tool for addressing drug development…
How Nanoform is Shaping a Greener Future for Pharma
In order to truly benefit patients and the world, it…
Feeling the Pressure: Polymorphism, Particle Size and Morphology Control Through Nanoparticle Crystallization Using Controlled Expansion of Supercritical Solutions
Our talented team presented their research at AAPS PharmSci 360…
Nanoform: small is green: utilizing innovative nanoparticle technologies To build a more sustainable pharmaceutical value chain
How can nanoparticle engineering build a more sustainable pharmaceutical value…
Feeling the pressure: nanoparticle crystallization using controlled expansion of supercritical solutions
Nanoforming improves bioavailabiliy by increasing the specific surface area of…
Financial Hearings webcast presentation at 15.00 EET
Report and presentation: https://nanoform.com/en/nanoform-q3-2023-nanoformed-blockbuster-drug-enters-clinic-and-another-nanoformed-drug-received-fda-orphan-designation/ Webcast: https://ir.financialhearings.com/nanoform-q3-report-2023 Telephone conference: https://conference.financialhearings.com/teleconference/?id=5005133